Related Experiment Video
Updated: Sep 3, 2025

09:22
In Vitro Aggregation Assays Using Hyperphosphorylated Tau Protein
Published on: January 2, 2015
18.5K
Neuronal nuclear tau and neurodegeneration
Alejandro Antón-Fernández1, Laura Vallés-Saiz1, Jesús Avila1
1Centro de Biología Molecular "Severo Ochoa", CSIC/UAM, Universidad Autónoma de Madrid, Cantoblanco, 28049 Madrid, Spain.
Neuroscience
|July 25, 2022
Summary
Tau protein, typically found in neuronal cytoplasm, also binds DNA in the cell nucleus. Increased nuclear tau during aging may accelerate aging by activating transposons.
Area of Science:
- Neuroscience
- Cell Biology
- Molecular Biology
Background:
- Tau is primarily known as a microtubule-associated protein in neuronal cytoplasm.
- Emerging evidence suggests tau's presence and function within the cell nucleus.
Purpose of the Study:
- To investigate the nuclear localization and potential DNA-binding properties of tau protein.
- To explore the implications of nuclear tau accumulation in the aging process.
Main Methods:
- The study likely involved techniques to detect and characterize tau protein within the cell nucleus.
- Methods may include DNA-binding assays and analysis of tau's interaction with specific genomic regions.
Main Results:
- Tau protein exhibits preferential binding to DNA sequences within the nucleolus and pericentromeric heterochromatin.
- An increase in nuclear tau levels is observed during cellular aging.
Conclusions:
- Nuclear tau functions as a nucleic acid-associated protein, distinct from its cytoplasmic role.
- The accumulation of nuclear tau during aging is potentially linked to transposon activation and accelerated aging.
More Related Videos
Related Concept Videos
Alzheimer's Disease: Overview
663
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
663
Neural Regulation
39.8K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.8K
Parkinson's Disease: Overview
690
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
690
Disorders of the Nervous Tissue
1.5K
Nervous tissue is a vital component of the human body's communication system, enabling us to perceive and respond to stimuli. However, like all other tissues, it is vulnerable to disorders and diseases that can significantly impact our neurological functioning.
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
Homeostatic Imbalances:
Alzheimer's disease manifests as a gradual decline in memory and cognitive abilities, attributed to the buildup of amyloid plaques and neurofibrillary tangles in the brain.
Parkinson's disease arises from the...
1.5K
Alzheimer's Disease: Treatment
258
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
258

